Eli Lilly disclosed late‑stage data showing its triple‑agonist retatrutide produced exceptionally large weight losses in obesity trials, including multi‑percent reductions that exceeded expectations. In patients with obesity and knee osteoarthritis one dataset reported ~23.7% mean weight loss and marked pain reductions; a separate Phase 3 readout cited up to 28.7% weight loss. However, the company also reported higher discontinuation rates and tolerability signals versus earlier studies. The readouts reaffirm retatrutide’s potency and push efficacy benchmarks for next‑generation incretin and multi‑agonist molecules. At the same time, safety and discontinuation signals will shape dosing strategies, label discussions, commercial positioning and payer negotiations. Sources: clinical data releases and coverage from clinical meeting reports.